Claim · model-written summary
HPLC-MS confirmed that strain D-1 produces the fengycin, iturin and surfactin lipopeptides.
- Taxon
- Bacillus amyloliquefaciens D-1
.jpg?width=60)
Bacillus amyloliquefacienst0 - Outcome
- production of these LPse0
Not reportedMaterialGeneCompoundOrgan / stageInteractorInteractor roleSecond interactorSecond interactor roleTreatmentComparatorSettingDirectionValueQualifier
Organisms pictured · Representative pictures of the matched species, not figures from the paper.
.jpg?width=500)
Verbatim
e0“HPLC-MS confirmed the production of these LPs”
t0“Bacillus amyloliquefaciens D-1”
Title
Haixia Shi; Shihua Zhou; Yanping Gao; et al. Frontiers in Microbiology 2026. doi:10.3389/fmicb.2026.1732585
Other claims from this paper (9)
- Observation Cell-free fermentation supernatant (Bf) of strain D-1 inhibited Alternaria alternata by 54.7% in vitro.
- Observation Genome analysis of strain D-1 revealed nine putative biosynthetic gene clusters, including those for fengycin, iturin and surfactin.
- Observation The lipopeptides disrupted hyphal branching and spore germination of Alternaria alternata.
- Intervention effect In pot trials crude lipopeptide extracts reduced disease lesion area by 92.0% in P. heterophylla.
- Intervention effect Crude lipopeptide extracts suppressed key mycotoxin biosynthesis genes (PKSJ, PKSA, etc.) of A. alternata in pot trials.
- Intervention effect Crude lipopeptide extracts reduced toxin levels (ALT, AME, TeA, TEN) by 77.0–98.1% in pot trials.
- Intervention effect Strain D-1 and its lipopeptides triggered systemic resistance in P. heterophylla, evidenced by elevated H2O2 accumulation and callose deposition.
- Mechanism The authors conclude B. amyloliquefaciens D-1 is a novel biocontrol agent with triple mechanisms: direct antifungal action, suppression of mycotoxin biosynthesis and induction of host systemic resistance.
- Recommendation The authors state that applying D-1 offers a sustainable strategy to manage A. alternata in P. heterophylla cultivation.